ATAI Life Sciences NV, a Berlin-based clinical-stage biopharmaceutical company, focuses on developing treatments for mental health disorders and went public on June 18, 2021. Key compounds include PCN-101 for treatment-resistant depression and DMX-1002 for opioid use disorder.
ATAI Life Sciences N.V. (ATAI) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, ATAI Life Sciences N.V.'s actual EPS was -$0.24, missing the estimate of -$0.15 per share, resulting in a -62.27% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
